Date of preparation: 06/14/11

SECTION I

Manufacturer	: W. R. MEA	ADOWS _® , I	NC.		- H M I S -			
ddress : 300 Industrial Dr. : Hampshire, IL 60140				je	lealth Iammability Reactivity	: 1 : 1 : 0		
Telephone # Emergency #	: (847) 683-4500 : 1-800-424-9300 Chemtrec			(Userand Da	(Hazard Rating: 0=Least,1=Slight,2=Moderate,3=High,4=Extreme,*=Chronic)			
Mfg. code I.D.	: 4703023			(nazaru ka	ting: u=Leas	st, i=Slight,z=woderate,	5=⊓ign,4=⊏xti	reme, "=Chronic)
Trade Name	: DECK-O-S	SEAL _® 125	SETTING	G AGENT - TAN				
SECTION II-A		HAZA	RDO		NENTS			
				% by	SARA	VAPOR PRESSURE	LEL	
No. Component		C	CAS#	Weight	313	(mm Hg @ 20 C)	(@ 25 C)	
 Diethylene Glycol I 	Dibenzoate	12	0-55-8	10-15	NO	N/A	N/A	
2. Dipropylene Glycol	l Dibenzoate	271	38-31-4	10-15	NO	N/A	N/A	
3. Titanium Dioxide		134	63-67-7	5-10	NO	N/A	N/A	
1. Limestone		131	17-65-3	45-50	NO	N/A	N/A	
5. Bisphenol A/Epichl	lorohydrin Resi	n 250	68-38-6	10-15	NO	N/A	N/A	
6. Dimethylbenzyl Hy)-15-9	5-10	YES	2.00	N/A	
None of the componen Jnder the reporting re	nts of this produce quirements of	uct are reco Section 313	gnized as 3 of Title	s carcinogenic. III of the Superfu	ind Amendme	N/A = Not Applicable ents and Reauthorization		SARA) and 40 CFR Pa
None of the componen Jnder the reporting re 372, chemicals listed o	nts of this produce quirements of	uct are reco Section 313 (40 CFR Pa	gnized as 3 of Title art 373.6	s carcinogenic. III of the Superfu	nd Amendme nder the head	N/A = Not Applicable ents and Reauthorization ling "SARA 313".		SARA) and 40 CFR Pa
None of the component Jnder the reporting re 1872, chemicals listed of	nts of this produce quirements of	uct are reco Section 313 (40 CFR Pa	gnized as 3 of Title art 373.6	s carcinogenic. III of the Superfu 5) are identified ur	nd Amendme nder the head	N/A = Not Applicable ents and Reauthorization ling "SARA 313".		SARA) and 40 CFR Pa
None of the componen Under the reporting re 172, chemicals listed c SECTION II-B	of this produ quirements of on the 313 List OSHA PEL/CEILING	Let are reco Section 313 (40 CFR Pa OCCI PEL/STEL	gnized as 3 of Title art 373.6 UPAT SKIN	s carcinogenic. III of the Superfu 5) are identified ur IONAL EXP TLV/TWA	nd Amendmender the head	N/A = Not Applicable ents and Reauthorization ling "SARA 313". LIMITS ACGIH IG TLV/STEL	Act of 1986 (SARA) and 40 CFR Pa
None of the component Juder the reporting re B72, chemicals listed component SECTION II-B No. PEL/TWA P . N/E	of this production of this production of the state of the	Act are reco Section 313 (40 CFR Pa OCCI PEL/STEL N/E	gnized as 3 of Title art 373.6 UPAT SKIN N/E	s carcinogenic. III of the Superfu 5) are identified un IONAL EXP TLV/TWA N/E	nd Amendme nder the head OSURE TLV/CEILIN N/E	N/A = Not Applicable ents and Reauthorization ling "SARA 313". LIMITS ACGIH IG TLV/STEL N/E	Act of 1986 (SKIN N/E	SARA) and 40 CFR Pa
None of the componen Under the reporting re B72, chemicals listed c SECTION II-B No. PEL/TWA P I. N/E 2. N/E	OSHA OSHA EL/CEILING N/E N/E	Act are reco Section 313 (40 CFR Pa OCCO PEL/STEL N/E N/E	gnized as 3 of Title art 373.65 UPAT SKIN N/E N/E	s carcinogenic. III of the Superfu 5) are identified un IONAL EXP TLV/TWA N/E N/E	nd Amendme nder the head OSURE TLV/CEILIN N/E N/E	N/A = Not Applicable ents and Reauthorization ling "SARA 313". LIMITS ACGIH IG TLV/STEL N/E N/E	Act of 1986 (SKIN N/E N/E	SARA) and 40 CFR Pa
None of the componen Jnder the reporting re 372, chemicals listed c SECTION II-B No. PEL/TWA P I. N/E 2. N/E 3. 15 mg/m ^{3**} ++	OSHA OSHA EL/CEILING N/E N/E N/E N/E	Act are reco Section 313 (40 CFR Pa OCCI PEL/STEL N/E	gnized as 3 of Title art 373.6 UPAT SKIN N/E	s carcinogenic. III of the Superfu 5) are identified un IONAL EXP TLV/TWA N/E N/E 10 mg/m ^{3**}	nd Amendme nder the head OSURE TLV/CEILIN N/E	N/A = Not Applicable ents and Reauthorization ling "SARA 313". LIMITS ACGIH IG TLV/STEL N/E	Act of 1986 (SKIN N/E	SARA) and 40 CFR Pa
None of the componen Jnder the reporting re 372, chemicals listed c SECTION II-B No. PEL/TWA P 1. N/E 2. N/E 3. 15 mg/m ^{3**} ++ 4. 15 mg/m ^{3**}	OSHA PEL/CEILING N/E N/E 5 mg/m ³ N/E	Act are reco Section 313 (40 CFR Pa OCC PEL/STEL N/E N/E N/E N/E N/E N/E	gnized as 3 of Title art 373.65 UPAT SKIN N/E N/E N/E N/E N/E N/E N/E	s carcinogenic. III of the Superfu b) are identified un IONAL EXP TLV/TWA N/E 10 mg/m ^{3**} 10 mg/m ^{3**} N/E	TLV/CEILIN N/E N/E N/E N/E N/E N/E N/E	N/A = Not Applicable ents and Reauthorization ling "SARA 313". LIMITS ACGIH IG TLV/STEL N/E N/E N/E N/E N/E N/E N/E	Act of 1986 (SKIN N/E N/E N/E N/E N/E	SARA) and 40 CFR Pa
None of the componen Under the reporting re 372, chemicals listed of SECTION II-B No. PEL/TWA P 1. N/E 2. N/E 3. 15 mg/m ^{3**} ++ 4. 15 mg/m ^{3**} 5. N/E 6. N/E	OSHA PEL/CEILING N/E N/E 5 mg/m ³ N/E N/E N/E N/E	Act are reco Section 313 (40 CFR Pa OCC PEL/STEL N/E N/E N/E N/E N/E N/E N/E	gnized as 3 of Title art 373.68 UPAT SKIN N/E N/E N/E N/E N/E N/E	s carcinogenic. III of the Superfu b) are identified un IONAL EXP TLV/TWA N/E 10 mg/m ^{3**} 10 mg/m ^{3**} N/E N/E N/E	TLV/CEILIN N/E N/E N/E N/E N/E N/E N/E N/E	N/A = Not Applicable ents and Reauthorization ling "SARA 313". LIMITS ACGIH IG TLV/STEL N/E N/E N/E N/E N/E	Act of 1986 (SKIN N/E N/E N/E N/E	SARA) and 40 CFR Pa
None of the componen Jnder the reporting re 372, chemicals listed c SECTION II-B No. PEL/TWA P 1. N/E 2. N/E 3. 15 mg/m ^{3**} ++ 4. 15 mg/m ^{3**} 5. N/E 6. N/E N/E = Not established	OSHA PEL/CEILING N/E N/E 5 mg/m ³ N/E N/E N/E N/E	Act are reco Section 313 (40 CFR Pa OCC OCC N/E N/E N/E N/E N/E N/E N/E N/E N/E N/E	gnized as 3 of Title art 373.64 UPAT SKIN N/E N/E N/E N/E N/E N/E N/E N/E N/E N/	s carcinogenic. III of the Superfu are identified un IONAL EXP TLV/TWA N/E 10 mg/m ^{3**} N/E N/E N/E mg/m ³ Respirable	TLV/CEILIN N/E N/E N/E N/E N/E N/E N/E N/E	N/A = Not Applicable ents and Reauthorization ling "SARA 313". LIMITS ACGIH IG TLV/STEL N/E N/E N/E N/E N/E N/E N/E	Act of 1986 (SKIN N/E N/E N/E N/E N/E	SARA) and 40 CFR Pa
None of the componen Jinder the reporting re 372, chemicals listed of SECTION II-B No. PEL/TWA P I. N/E 2. N/E 3. 15 mg/m ^{3**} ++ 4. 15 mg/m ^{3**} 5. N/E 5. N/E N/E = Not established SECTION III	OSHA PEL/CEILING N/E N/E 5 mg/m ³ N/E 5 mg/m ³ N/E ** = To	Act are reco Section 313 (40 CFR Pa OCCI PEL/STEL N/E N/E N/E N/E N/E N/E N/E N/E N/E N/E	gnized as 3 of Title art 373.64 UPAT SKIN N/E N/E N/E N/E N/E N/E N/E N/E N/E N/	s carcinogenic. III of the Superfu are identified ur IONAL EXP TLV/TWA N/E 10 mg/m ^{3**} 10 mg/m ^{3**} N/E mg/m ³ Respirable DATA	TLV/CEILIN N/E N/E N/E N/E N/E N/E N/E E fraction	N/A = Not Applicable ents and Reauthorization ling "SARA 313". LIMITS ACGIH IG TLV/STEL N/E N/E N/E N/E N/E N/E N/E N/E N/E	Act of 1986 (SKIN N/E N/E N/E N/E N/E	SARA) and 40 CFR Pa
None of the componen Jnder the reporting re 372, chemicals listed of SECTION II-B No. PEL/TWA P I. N/E 2. N/E 3. 15 mg/m ^{3**} ++ 4. 15 mg/m ^{3**} 5. N/E 5. N/E	OSHA PEL/CEILING N/E N/E 5 mg/m ³ N/E N/E ** = To : Not es	Act are reco Section 313 (40 CFR Pa OCCU PEL/STEL N/E N/E N/E N/E N/E N/E N/E N/E Stablished	gnized as 3 of Title art 373.64 UPAT SKIN N/E N/E N/E N/E N/E N/E N/E N/E N/E N/	s carcinogenic. III of the Superfu are identified ur IONAL EXP TLV/TWA N/E 10 mg/m ^{3**} 10 mg/m ^{3**} N/E M/E mg/m ³ Respirable DATA % Volatile	TLV/CEILIN N/E N/E N/E N/E N/E N/E E fraction	N/A = Not Applicable ents and Reauthorization ling "SARA 313". LIMITS ACGIH IG TLV/STEL N/E N/E N/E N/E N/E N/E N/E N/E N/E N/E	Act of 1986 (SKIN N/E N/E N/E N/E N/E	SARA) and 40 CFR Pa
None of the componen Under the reporting re 372, chemicals listed of SECTION II-B No. PEL/TWA P 1. N/E 2. N/E 3. 15 mg/m ^{3**} ++ 4. 15 mg/m ^{3**} 5. N/E 6. N/E 8. N/E N/E = Not established SECTION III Boiling Point Evaporation Rate	OSHA PEL/CEILING N/E N/E N/E N/E N/E N/E N/E N/E N/E N/E	Act are reco Section 313 (40 CFR Pa OCCU PEL/STEL N/E N/E N/E N/E N/E N/E tal dust PHYS stablished ether = 1)	gnized as 3 of Title art 373.64 UPAT SKIN N/E N/E N/E N/E N/E N/E N/E N/E N/E N/	s carcinogenic. III of the Superfu are identified ur IONAL EXP TLV/TWA N/E 10 mg/m ^{3**} N/E 10 mg/m ^{3**} N/E mg/m ³ Respirable DATA % Volatile % Volatile	TLV/CEILIN N/E N/E N/E N/E N/E N/E N/E N/E by volume by weight	N/A = Not Applicable ents and Reauthorization ling "SARA 313". LIMITS ACGIH IG TLV/STEL N/E N/E N/E N/E N/E N/E N/E N/E N/E N/E	Act of 1986 (SKIN N/E N/E N/E N/E N/E N/E	SARA) and 40 CFR Pa
None of the componen Under the reporting re 372, chemicals listed c SECTION II-B No. PEL/TWA P 1. N/E 2. N/E 3. 15 mg/m ^{3**} ++ 4. 15 mg/m ^{3**}	OSHA PEL/CEILING N/E N/E N/E N/E N/E N/E N/E N/E ** = To : Not en : < 1 (e : > 1 (a	Act are reco Section 313 (40 CFR Pa OCCU PEL/STEL N/E N/E N/E N/E N/E N/E tal dust PHYS stablished ether = 1)	gnized as 3 of Title art 373.64 UPAT SKIN N/E N/E N/E N/E N/E N/E N/E N/E N/E N/	s carcinogenic. III of the Superfu are identified ur IONAL EXP TLV/TWA N/E 10 mg/m ^{3**} 10 mg/m ^{3**} N/E M/E mg/m ³ Respirable DATA % Volatile	TLV/CEILIN N/E N/E N/E N/E N/E N/E N/E N/E by volume by weight	N/A = Not Applicable ents and Reauthorization ling "SARA 313". LIMITS ACGIH IG TLV/STEL N/E N/E N/E N/E N/E N/E N/E N/E N/E N/E	Act of 1986 (SKIN N/E N/E N/E N/E N/E N/E	SARA) and 40 CFR Pa

EYE CONTACT: This product may cause mild to moderate eye irritation. Corneal injury is unlikely.

SKIN CONTACT: Based on the presence of component 5 contact with the skin may result in skin sensitization to epoxies. Individuals who have developed a skin sensitization can develop these symptoms as a result of contact with very small amounts of liquid material or as a result of exposure to vapor. This skin sensitization may be temporary or permanent. Once an individual is diagnosed as being sensitized, no further exposure can be permitted.

INHALATION: Based on the presence of component 6 exposure to mist or spray may cause coughing, sneezing, or other symptoms of upper respiratory tract irritation. Overexposure may result in lung tissue damage due to corrosive effects. Based on the presence of component 5 as a result of repeated overexposures or exposure to a single large dose, certain individuals may develop lung sensitization (chemical asthma) to epoxies which will cause them to react to a later exposure at very low levels. Once an individual is diagnosed as being sensitized, no further exposure can be permitted. This lung sensitization may be either temporary or permanent.

INGESTION: This product may produce moderate irritation of the digestive tract.

SIGNS AND SYMPTOMS: Symptoms of eye irritation include pain, tearing, reddening, and swelling. Symptoms of skin irritation include reddening, swelling, rash, and redness. Symptoms of respiratory irritation include runny nose, sore throat, coughing, chest discomfort, shortness of breath, and reduced lung function. Symptoms of gastrointestinal irritation include sore throat, abdominal pain, nausea, vomiting, and diarrhea. Skin sensitization results in allergic dermatitis which may include rash, itching, hives and swelling of extremities. Lung sensitization results in asthma-like symptoms: chest tightness, shortness of breath, wheezing and coughing. These symptoms may be immediate or delayed up to several hours.

*** MATERIAL SAFETY DATA SHEET ***

Date of preparation: 06/14/11

Based on the presence of component 3 symptoms of silicosis may include shortness of breath, difficulty breathing with/without exertion, coughing, diminished work capacity, reduction of lung volume, and right heart enlargement and/or failure.

AGGRAVATED MEDICAL CONDITIONS: Pre-existing skin, eye, and respiratory disorders may be aggravated by exposure to this product. Persons with asthmatic-type conditions, chronic bronchitis, other chronic respiratory diseases, recurrent skin eczema, sensitization or allergies should be excluded from working with epoxies.

OTHER HEALTH EFFECTS: None known.

SECTION V

EMERGENCY AND FIRST AID PROCEDURES

EYE CONTACT: If irritation or redness develops, move victim away from exposure source and into fresh air. Flush eyes with water for fifteen (15) minutes. If symptoms persist, seek medical attention.

SKIN CONTACT: Remove contaminated shoes and clothing. Cleanse affected area(s) thoroughly by washing with mild soap and water. If irritation or redness develops and persists, seek medical attention.

INHALATION: If respiratory symptoms develop, move victim away from exposure source and into fresh air. If symptoms persist, seek medical attention. If victim is not breathing, immediately begin artificial respiration. If breathing difficulties develop, oxygen should be administered by qualified personnel. Seek immediate medical attention.

INGESTION: Do not induce vomiting. If vomiting spontaneously occurs, keep the victim's head below the hips to prevent aspiration into the lungs. Since aspiration into the lungs can cause very serious, permanent damage, the decision of whether to induce vomiting or not should be made by a physician. Damage from lung aspiration must be weighed against toxicity when considering emptying the stomach. Consult a physician, hospital, or poison control center and/or transport to an emergency facility immediately.

SECTION VI FIRE AND EXPLOSION HAZARDS

FLAMMABILITY CLASSIFICATION

- NFPA: Not regulated - DOT: Not regulated

FLASH POINT: Greater than 210 degrees F

EXTINGUISHING MEDIA: Use water fog, foam, dry chemical, or Carbon Dioxide.

SPECIAL FIRE FIGHTING PROCEDURES AND PRECAUTIONS: Clear area of unprotected personnel. Do not enter confined fire space without helmet, face shield, bunker coat, gloves, rubber boots, and a positive pressure NIOSH approved self-contained breathing apparatus.

UNUSUAL FIRE AND EXPLOSION HAZARDS: Containers exposed to intense heat from fires should be cooled with water to prevent vapor pressure buildup which may result in container rupture. Container areas exposed to direct flame contact should be cooled with large quantities of water as needed to prevent weakening of container structure.

SECTION VII REACTIVITY

STABILITY: Stable

HAZARDOUS POLYMERIZATION: Will not occur

CONDITIONS AND MATERIALS TO AVOID: Avoid oxidizing materials, strong acids, lead, copper, and their alloys, zinc, amines, polyamines, and polyamides under uncontrolled conditions

HAZARDOUS DECOMPOSITION PRODUCTS: Combustion may yield Carbon Dioxide, Carbon Monoxide, and/or incomplete combustion products. Do not breathe smoke or fumes. Wear appropriate protective equipment.

SECTION VIII EMPLOYEE PROTECTION

RESPIRATORY PROTECTION: Use ventilation as required to control vapor concentrations - at least 10 air changes per hour are recommended for good general room ventilation. If exposure exceeds the PEL/TLV, use the appropriate NIOSH approved respirator.

PROTECTIVE CLOTHING: Wear safety glasses, goggles, or a splash shield to prevent eye contact. Contact lenses should not be worn. Wear appropriate gloves and protective clothing to prevent contact with skin and clothing.

ADDITIONAL PROTECTIVE MEASURES: Eye wash fountains and safety showers should be available for use in an emergency.

SECTION IX ENVIRONMENTAL PROTECTION

SPILL OR LEAK PROCEDURES: LARGE SPILLS>> Evacuate the hazard area of unprotected personnel. Wear appropriate respirator and protective clothing. Shut off source of leak only if safe to do so. Dike and contain. If vapor cloud forms, water fog may be used to suppress; contain run-off.

Remove with vacuum trucks or pump to storage/salvage vessels. Soak up residue with an absorbent such as clay, sand, or other suitable material;

place in non-leaking containers for proper disposal. Flush area with water to remove trace residue; dispose of flush solutions as above. SMALL

SPILLS>> Take up with an absorbent material and place in non-leaking containers; seal tightly for proper disposal.

WASTE DISPOSAL: Observe all Federal, State and local regulations regarding proper disposal.

SECTION X ADDITIONAL PRECAUTIONS

Containers can contain hazardous product residues even when empty. Wash with soap and water before eating, drinking, smoking or using toilet facilities.

The information contained herein is based on the data available to us and is believed to be correct. However, we make no warranty, expressed or implied regarding the accuracy of this data or the results to be obtained from the use thereof. We assume no responsibility for injury from the use of the product described herein.